Shay Shemesh, Chief Development & Operations Officer at Nuvectis Pharma, Inc. (NVCT), bought 420 shares at $11.99 ($5K) on 2023-03-21, disclosed to the SEC on 2023-03-22.
Open-market purchase of $5k NVCT by Chief Development & Operations Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2022-12-22 | $4K | — | Filing → |
| NVCT | BUY | 2022-11-18 | $2K | — | Filing → |
| NVCT | BUY | 2022-09-27 | $2K | — | Filing → |